LAVA Therapeutics NV Total Liabilities
LAVA Therapeutics NV total liabilities. Based on the latest financial reports, LAVA Therapeutics NV (LVTX) has total liabilities worth $39.23 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LVTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of LAVA Therapeutics NV (2019–2024)
Total liabilities of LAVA Therapeutics NV from 2019 to 2024. This chart illustrates how LAVA Therapeutics NV's total liabilities have evolved over time, based on quarterly financial data.
LAVA Therapeutics NV Competitors by Total Liabilities
The table below lists competitors of LAVA Therapeutics NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taiwan Taffeta Fabric Co Ltd
TW:1454
|
Taiwan | NT$680.53 Million |
|
LGL Group Inc
NYSE MKT:LGL
|
USA | $1.49 Million |
|
Mercal Inmuebles Socimi SA
MC:YMEI
|
Spain | €22.22 Million |
|
Hyundai Industrial Co. Ltd
KQ:170030
|
Korea | ₩82.12 Billion |
|
I-Hwa Industrial Co Ltd
TW:1456
|
Taiwan | NT$11.68 Billion |
|
Deswell Industries Inc
NASDAQ:DSWL
|
USA | $20.57 Million |
|
ImageneBio, Inc.
NASDAQ:IMA
|
USA | $9.97 Million |
|
PS Tec. Co. Ltd
KQ:002230
|
Korea | ₩38.95 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down LAVA Therapeutics NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LAVA Therapeutics NV (LVTX) total assets.
Liquidity & Leverage Metrics
LAVA Therapeutics NV Total Liabilities Ratios Explained
LAVA Therapeutics NV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LAVA Therapeutics NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LAVA Therapeutics NV (2019–2024)
The table below shows the annual total liabilities of LAVA Therapeutics NV from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $53.09 Million | +5.05% |
| 2023-12-31 | $50.53 Million | -11.94% |
| 2022-12-31 | $57.38 Million | +174.83% |
| 2021-12-31 | $20.88 Million | +62.30% |
| 2020-12-31 | $12.87 Million | +335.66% |
| 2019-12-31 | $2.95 Million | -- |
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more